Antipsychotics' effects on blood levels of cytokines in schizophrenia: A meta-analysis

Tourjman, Valérie; Kouassi, Édouard; Koué, Marie-Ève; Rocchetti, Matteo; Fortin-Fournier, Simon; Fusar‐Poli, Paolo; Potvin, Stéphane

doi:10.1016/j.schres.2013.10.011

Cited by 190 publications

(143 citation statements)

References 35 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…These differences may be due to the significantly shorter duration of illness in our study population, the possible predominance of IL-6 signalling pathways in later stages of schizophrenia (14), and the diverse effects of different antipsychotic drugs (21). The meta-analysis by Tourjman et al (53) confirms our findings that TGF-β is unaffected by antipsychotic treatment (23).…”

Section: Tgf-β In Schizophreniasupporting

confidence: 80%

Possible Role of TGF – B Pathways in Schizophrenia / Moguća Uloga TTGF - B Signalnih Puteva U Shizofreniji

Borovcanin

Jovanović

Dejanovic

et al. 2016

Serbian Journal of Experimental and Clinical Research

View full text Add to dashboard Cite

show abstract

Section: Tgf-β In Schizophreniasupporting

confidence: 80%

Possible Role of TGF – B Pathways in Schizophrenia / Moguća Uloga TTGF - B Signalnih Puteva U Shizofreniji

Borovcanin

Jovanović

Dejanovic

et al. 2016

Serbian Journal of Experimental and Clinical Research

View full text Add to dashboard Cite

show abstract

“…The latter was considered consistent with the anti-inflammatory role associated with antipsychotics [20]. In contrast, in a more recent study, an increase in INF-γ levels was observed over 12 weeks of treatment with atypical antipsychotics in FEP patients [33].…”

Section: Immunoinflammatory Biomarkerssupporting

confidence: 51%

“…A meta-analysis demonstrated in a quantitative manner that a 4 to 8 week-treatment with antipsychotics (typical, atypical or mixed) led to increases in sIL-2R and decreases in IL-1β and IFN-γ blood levels [20]. The latter was considered consistent with the anti-inflammatory role associated with antipsychotics [20].…”

Section: Immunoinflammatory Biomarkersmentioning

confidence: 98%

“…Several data support the inflammatory hypothesis in SCZ's pathophysiology. It is characterised by enhanced innate immune response with overproduction and/or imbalance of cytokines, namely an increase in pro-inflammatory and a decrease in anti-inflammatory cytokines [14,[18][19][20]. Cytokines, key signaling molecules of the immune system, exert their effects by binding specific receptors on a variety of peripheral and brain target cells [21].…”

Section: Immunoinflammatory Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers and schizophrenia: a qualitative review

Silva¹,

Pinto²

2017

IJCNMH

View full text Add to dashboard Cite

Schizophrenia (SCZ) is a psychiatric disorder with a broad spectrum of biological and clinical manifestations of yet not completely clear pathophysiological mechanisms. Several lines of evidence have been supporting the idea that immunoinflammatory, oxidative, hormonal and cellular dysfunctions are implicated on the biomolecular basis of SCZ. However, accurate diagnosis and selection of appropriate treatments remains challenging as a result of the scarcity of objective tests. Furthermore, there is a compelling need to find biomarkers that could predict drug response and tailor pharmacological treatment, particularly in drug-naïve first episode psychosis (FEP). Hence, numerous technologies have been employed in order to search for SCZ biological markers, but evidence relating them to treatment efficacy is lacking. In this regard, some preliminary data suggest promising results. The current review provides information on: (1) potential biomarkers associated with biological disturbances and (2) biological markers associated with treatment response.

show abstract

“…However, a recent meta-analysis 60 reported that antipsychotic treatment significantly decreases IL-1β, IL-6 and TGF-β, but increase sIL-2R and IL-12 levels in schizophrenia patients. A more recent meta-analysis showed that antipsychotic treatment significantly increases plasma levels of sIL-2Rand reduces the plasma levels of IL-1β and IFN-γ 129 .…”

mentioning

confidence: 99%

Neuroinflammation in Schizophrenia Focused on the Pharmacological and Therapeutic Evidence

Xu¹

2015

Pharmacologia

View full text Add to dashboard Cite

Background: Schizophrenia is a heterogeneous mental disorder with a variety of symptoms. Although, there are no pathognomonic abnormalities in brains of schizophrenia patients, recent years have witnessed research progresses in revealing pathologic changes in cellular and molecular levels. Objective: This article reviewed recent human studies showing neuroimmune alterations in schizophrenia patients and offered explanations for roles of neuroinflammation in the pathogenesis of schizophrenia by citing some of experimental data from non-human studies. The focus of this review was put on pharmacological and therapeutic evidence pointing to a recommendation of anti-inflammatory treatment for patients with schizophrenia. Particularly, it provided compelling evidence supporting an anti-inflammatory effect of antipsychotics by reviewing a relatively large body of studies in the categories of in vitro, animals and humans. Conclusion: Then, it reviewed recent clinical trials with minocycline, a second-generation tetracycline, or the selective COX-2 inhibitor celecoxib. Most of these clinical trials provided promising results of superior beneficial treatment effects as the consequence of co-administration of standard antipsychotic drugs and anti-inflammatory compounds, compared with antipsychotic drugs alone.

show abstract

Antipsychotics' effects on blood levels of cytokines in schizophrenia: A meta-analysis

Cited by 190 publications

References 35 publications

Possible Role of TGF – B Pathways in Schizophrenia / Moguća Uloga TTGF - B Signalnih Puteva U Shizofreniji

Possible Role of TGF – B Pathways in Schizophrenia / Moguća Uloga TTGF - B Signalnih Puteva U Shizofreniji

Biomarkers and schizophrenia: a qualitative review

Neuroinflammation in Schizophrenia Focused on the Pharmacological and Therapeutic Evidence

Contact Info

Product

Resources

About